Bionano Genomics, Inc. BNGO
Set alert
As of Nov 3, 10:55 AM ET
- YTD
- -22.22%
- 1 year
- -30.81%
- Open
- 1.16
- Prev close
- 1.16
- Mkt cap
- 16.63M
- Vol
- 24.31K
- Avg vol
- 941.89K
- EPS
- -3.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.16
- High
- 1.20
- Forward P/E
- -0.41
- Beta
- 2.38
- Short ratio
- 3.81
- Inst. own
- 12.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 0.2652
- 200-d avg
- 0.6133
- 1y target
- 1.00
5D chart
Signals (32)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 3:05 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 2:40 PM | 20 hours ago |
| RSI: Oversold | Nov 2, 2:40 PM | 20 hours ago |
| MACD: Buy Signal | Nov 2, 1:30 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 11:25 AM | 23 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 30, 11:15 AM | 4 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 30, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 4 days ago |
Newest 20 of 32.
News
6 days ago globenewswire.com
Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m.…
1 month ago globenewswire.com
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs),…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…
1 month ago benzinga.com
Bionano Genomics Stock Surges Tuesday: What's Going On?
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
-
1 month ago benzinga.com
Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies —…
1 month ago globenewswire.com
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically…
-
1 month ago benzinga.com
Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that…
1 month ago globenewswire.com
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs),…
1 month ago globenewswire.com
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders,…
2 months ago globenewswire.com
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global…
2 months ago seekingalpha.com
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est
Bionano Genomics (NASDAQ:BNGO) raises FY2026 sales outlook from $30.000 million-$33.000 million to $31.000 million-$33.000 million vs $32.137 million estimate.
3 months ago globenewswire.com
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m.…
4 months ago globenewswire.com
Bionano Announces Hiring of Chief Scientific Officer
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief…
4 months ago globenewswire.com
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics…
4 months ago globenewswire.com
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that…
4 months ago zacks.com
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 months ago zacks.com
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are…
5 months ago globenewswire.com
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the…
5 months ago globenewswire.com
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM)…
5 months ago seekingalpha.com
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago.
5 months ago benzinga.com
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call
-
5 months ago benzinga.com
Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.95) by 20 percent. This is a 33.91 percent increase over losses of…
-
5 months ago benzinga.com
Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est
Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $30.000 million-$33.000 million to $30.000 million-$33.000 million vs $32.137 million estimate.
5 months ago globenewswire.com
Bionano Reports First Quarter 2026 Results and Provides a Business Update
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with…
-
5 months ago benzinga.com
Bionano Genomics Files Shelf Registration To Offer Up To $400M In Common Stock, Preferred Stock, Debt, Warrants, And Units
$400,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsFrom time to time, we may offer and sell up to an aggregate amount of $400,000,000 of any combination of the securities described in…
-
6 months ago benzinga.com
Bionano Genomics Appoints Chairman Al Luderer Interim President, CEO, Effective Immediately
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May…
6 months ago globenewswire.com
Bionano Announces Leadership Transition
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim…
6 months ago globenewswire.com
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV…
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $7 to $6.
7 months ago benzinga.com
Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story
Bionano Genomics stock soared on Monday as investors anticipated the company's Q4 earnings report.
-
7 months ago benzinga.com
Earnings Scheduled For March 23, 2026
Earnings Scheduled For March 23, 2026
7 months ago benzinga.com
Nasdaq Tumbles 2% Amid Rate-Hike Fears: Fear & Greed Index Remains In 'Extreme Fear' Zone
The CNN Fear & Greed Index increased due to ongoing conflicts. U.S. stocks closed lower, with Nasdaq down 2%, while energy and financial sectors gained.
7 months ago benzinga.com
United Airlines, AGI And 3 Stocks To Watch Heading Into Monday
US stock futures down, Caledonia Mining, United Airlines & Agi to report earnings, Cheetah Net & BioNano Genomics to release results.
7 months ago benzinga.com
Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.
-
7 months ago benzinga.com
Bionano Announces Two-Fold Increase in OGM Studies Presented At Annual Clinical Genetics Meeting
Bionano Genomics participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold…
-
9 months ago benzinga.com
Bionano Genomics Publishes Study On Application Of Optical Genome Mapping To Trace Genomic Alterations Introduced By Different Gene Editing Technologies
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to…
-
11 months ago benzinga.com
Bionano Laboratories Gains 47% CMS Reimbursement Increase For OGM Blood-Cancer Test Code 81195 In 2026
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced…
11 months ago benzinga.com
Baidu To Rally More Than 69%? Here Are 10 Top Analyst Forecasts For Monday
Baidu To Rally More Than 69%? Here Are 10 Top Analyst Forecasts For Monday
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $7
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $11 to $7.
-
11 months ago benzinga.com
Bionano Genomics Affirms FY2025 Sales Guidance of $26.000M-$30.000M vs $28.136M Est
Bionano Genomics (NASDAQ:BNGO) affirms FY2025 sales outlook from $26.000 million-$30.000 million to $26.000 million-$30.000 million vs $28.136 million estimate.
-
11 months ago benzinga.com
Bionano Genomics Q3 EPS $(1.59) Beats $(1.91) Estimate, Sales $7.367M Beat $6.871M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.91) by 16.75 percent. This is a 94.86 percent increase over losses of…
-
11 months ago benzinga.com
Bionano Genomics Q3 Sales $7.367M Beat $6.871M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $7.367 million which beat the analyst consensus estimate of $6.871 million by 7.22 percent. This is a 21.31 percent increase over sales of…
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
12 months ago benzinga.com
Bionano Genomics Publishes Study Demonstrating That Optical Genome Mapping Can Overcome Key Limitations Of Targeted RNA-Sequencing Panels In Detecting Therapeutically Relevant Gene Rearrangements In Acute Leukemia
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address…
-
1 year ago benzinga.com
Bionano Genomics Highlighted Expanding Role Of Optical Genome Mapping In Genetic Disease Research At ASHG Conference
Bionano Genomics, Inc. (NASDAQ:BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the potential for an expanding…
1 year ago benzinga.com
Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge
Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge